Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05921292 · ClinicalTrials.gov registry record · Early Phase 1

Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies

A Early Phase 1 study, sponsored by Omeza.

Completed
Registry status
Early Phase 1
Development phase
111
Enrollment target

NCT05921292 is a Early Phase 1 study that has completed, run by Omeza. The registered enrollment target is 111 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05921292, a Early Phase 1 study, has completed, sponsored by Omeza.

COMPLETED
Registry status
Early Phase 1
Development phase
111 participants
Enrollment target

Study Summary

The goal of this clinical trial is to evaluate the use of Omeza combination therapy with Standard of Care. The main question it aims to answer is: \- Can Omeza combination therapy with Standard of Care enable chronic wounds to begin a healing trajectory in a 4-week period? Patients will be treated with: * OCM™ Wound Matrix * Omeza combination therapy * Standard of Care

Interventions

  • COMBINATION_PRODUCT Omeza Products Used in Combination

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2022-07-11
Est. Completion 2024-05-31
Phase Early Phase 1

Sponsor

Omeza

6 total trials

What the Registry Record Tells You About NCT05921292

The ClinicalTrials.gov registry entry for NCT05921292 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Omeza, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Omeza Products Used in Combination is the first listed.

NCT05921292 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05921292 about?

NCT05921292 is a clinical study titled "Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies". The goal of this clinical trial is to evaluate the use of Omeza combination therapy with Standard of Care. The main question it aims to answer is: \- Can Omeza combination therapy with Standard of Care enable chronic wounds to begin a healing trajectory in a 4-week period? Patients will be treated...

What is the current status of trial NCT05921292?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 111 participants. The study started on 2022-07-11. Estimated completion is 2024-05-31.

What interventions are being tested in trial NCT05921292?

The interventions under investigation include: Omeza Products Used in Combination (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05921292?

This trial is sponsored by Omeza, which has 6 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.